Carvedilol and alverine
Phase 3Small molecule
Carvedilol and alverine is one of 16 small molecule programs targeting Portal Hypertension. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
15
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
16 competitors in Portal Hypertension
#DrugCompanyPhaseTrials
1Coreg
Akero TherapeuticsApproved
Zocor
OOrganon and Co
Approved
Nexavar
BayerApproved
Sandostatin
Sun PharmaApproved
Baraclude
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Glucophage
EMD SeronoPhase 2
Cadonilimab
SShanghai Pharmaceuticals Holding Co., Ltd
Phase 2
Donafenib
SSuzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 2
Alverine
SShanghai Changzheng Hospital
Phase 3
Carvedilol and alverine
SShanghai Changzheng Hospital
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Carvedilol and alverine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- SShanghai Changzheng Hospital